Medicare Part D Could Alleviate “Bias” In Formulary Decisions
The use of pharmacy & therapeutics committees under the Medicare Part D drug benefit will help alleviate the bias sometimes seen in managed care decision making, Formulary Resources consultant Peter Penna suggested during the National Association of Chain Drug Stores' Medicare Prescription Drugs and Reform Conference in Baltimore March 3
You may also be interested in...
Medicare prescription drug plan pharmacy & therapeutics committees must consider the overall economic impact of coverage decisions - not just pharmacy costs - if they use pharmacoeconomic data in their analyses, the Centers for Medicare & Medicaid Services states in its final rule implementing Title I of the Medicare Modernization Act
The Medicare implementing regulations will have a profound impact on the operations of pharmacy and therapeutics committees, Medco Government Affairs Consultant Terry Latanich told the P&T Society's recent annual conference
Medco's $29.3 mil. settlement with 20 state attorneys general looks like a shrewd investment ahead of the Medicare prescription drug law scheduled to take effect in 2006